Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma

Summary

The primary objective was to evaluate the efficacy of rasburicase in terms of prevention and treatment of hyperuricemia related to Tumor Lysis Syndrome (TLS) in 2 populations of adult patients, previously treated or not with urate oxidase, with relapsing aggressive non-Hodgkin's lymphoma (NHL) and at risk of TLS, presenting with hyperuricemia and/or bulky disease at diagnostic of relapse. The secondary objectives were to : * evaluate the efficacy of rasburicase in terms of renal protection, * evaluate the safety of rasburicase in the two cohorts of patients, * correlate efficacy and safety results with antibodies generation/level.

Timeline

Start

2002-07

Primary completion

2005-01

Completion

2005-01

Drugs

Indications

No indication recorded.